



Attorney's Docket No. 3135 R1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Chen et al. )  
Serial No: 10/606,969 ) Group Art Unit: Unassigned  
Filed: 06/25/03 ) ) Examiner: Unassigned  
For: SHORT DURATION DEPOT FORMULATIONS )  
\_\_\_\_\_  
)

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit herewith patents, publications and other information of which they are aware, which they believe an examiner may consider to be material to the patentability of the claims of this application, and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

While this Information Disclosure Statement may contain "material" information pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is either "material" or "prior art" to the invention disclosed and claimed in the above-referenced application unless specifically designated as such. Applicants specifically reserve the right, where appropriate, to avoid or antedate any such reference by the appropriate arguments or showings under 37 C.F.R. § 1.131 and § 1.608, or any other appropriate means.

A completed PTO Form 1449 listing each reference which is not a U.S. Patent application is submitted herewith, and it respectfully requested that an Examiner initialed copy of the PTO Form 1449 be returned to the undersigned.

A copy of each reference therein listed accompanies this Information Disclosure Statement.

**-OR-**

NO copies of the references therein listed accompany this Information Disclosure Statement under 37 C.F.R. § 1.98(d), as each was previously cited by or submitted to the Patent Office in prior

application Serial No. 09/129,687, filed 08/05/98, which this application relies upon for an earlier filing date under 35 U.S.C. § 120.

This Information Disclosure Statement is not a representation that a search has been made or that no other information material to the patentability of this invention exists.

This Information Disclosure Statement is being filed within three months of the filing or entry of the national stage of this application, or before the mailing of a first Office Action on the merits, whichever is later. No fee is required under 37 C.F.R. § 1.97(b). However, in the event that more than 90 days from filing have elapsed and a first Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the fee required under 37 C.F.R. 1.17(p) to Deposit Account Number 01-1173.

This Information Disclosure Statement is being submitted *after* three months from the date of filing or entry of the national stage or this application, or *after* the mailing of a first Office Action, whichever is later, but *before* the mailing date of either a final Office Action or a Notice of Allowance.

The Commissioner is hereby authorized to charge the fee required under 37 C.F.R. § 1.17(p) to Deposit Account 10-0750.

**-OR-**

Certification as specified in 37 C.F.R. § 1.97(e) follows:

*Each* item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application no more than three months prior to the filing of this statement.

*No* item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The Examiner is hereby requested to consider these references and other information and make them of record in the above-referenced application. Applicants respectfully submit that the claims of this application are patentable over the above-cited references and information. Examination and allowance of this application at an early date are requested.

Respectfully submitted,

Date: 10/8/03


By:   
Samuel E. Webb, Reg. No. 44,394


ALZA Corporation c/o Johnson & Johnson  
1 Johnson & Johnson Plaza, WH 3221  
New Brunswick, NJ 08933  
Tel. 650-564-5106  
Fax. 650-564-2195

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313 on October 8, 2003.

ALZA CORPORATION

BY:   
Jolanta Pence



<b>INFORMATION DISCLOSURE CITATION</b> Sheet 1 of 1 PTO-1449			ATTORNEY'S DOCKET NO.:		APPLICATION NO.:	
			ARC 3135 R1		10/606,969	
			APPLICANT: <b>Chen et al.</b>			
FILING DATE: <b>06/25/03</b>			GROUP:			
<b>US PATENT DOCUMENTS</b>						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLAS S	FILING DATE
	<b>3,797,492</b>	<b>3/19/74</b>	<b>Place</b>	<b>128</b>	<b>260</b>	<b>12/27/72</b>
	<b>3,923,939</b>	<b>12/2/75</b>	<b>Baker et al.</b>	<b>264</b>	<b>49</b>	<b>6/7/74</b>
	<b>3,987,790</b>	<b>10/26/76</b>	<b>Eckenhoff et al.</b>	<b>128</b>	<b>260</b>	<b>10/1/75</b>
	<b>4,008,719</b>	<b>2/22/77</b>	<b>Theeuwes et al.</b>	<b>128</b>	<b>260</b>	<b>2/2/76</b>
	<b>4,443,340</b>	<b>4/17/84</b>	<b>May et al.</b>	<b>210</b>	<b>697</b>	<b>5/24/83</b>
	<b>4,586,559</b>	<b>2/4/86</b>	<b>Nuwayser et al.</b>	<b>427</b>	<b>3</b>	<b>2/6/84</b>
	<b>4,623,588</b>	<b>11/18/86</b>	<b>Nuwayser et al.</b>	<b>428</b>	<b>402.24</b>	<b>12/2/85</b>
	<b>4,668,506</b>	<b>5/26/87</b>	<b>Bawa</b>	<b>424</b>	<b>429</b>	<b>8/16/85</b>
	<b>4,708,861</b>	<b>11/24/87</b>	<b>Popescu et al.</b>	<b>424</b>	<b>1.1</b>	<b>1/31/85</b>
	<b>4,711,782</b>	<b>12/8/87</b>	<b>Okada et al.</b>	<b>424</b>	<b>455</b>	<b>12/11/86</b>
	<b>4,713,244</b>	<b>12/15/87</b>	<b>Bawa et al.</b>	<b>424</b>	<b>429</b>	<b>8/16/85</b>
	<b>4,853,218</b>	<b>8/1/89</b>	<b>Yim et al.</b>	<b>424</b>	<b>85.7</b>	<b>2/24/87</b>
	<b>4,865,845</b>	<b>9/12/89</b>	<b>Eckenhoff et al.</b>	<b>424</b>	<b>424</b>	<b>9/12/89</b>
	<b>4,866,050</b>	<b>9/12/89</b>	<b>Ben-Amoz</b>	<b>514</b>	<b>179</b>	<b>4/27/88</b>
	<b>4,931,279</b>	<b>6/5/90</b>	<b>Bawa et al.</b>	<b>424</b>	<b>427</b>	<b>7/21/88</b>
	<b>4,938,763</b>	<b>7/3/90</b>	<b>Dunn et al.</b>	<b>604</b>	<b>891.1</b>	<b>10/03/88</b>
	<b>4,985,404</b>	<b>1/15/91</b>	<b>Mitchell et al.</b>	<b>514</b>	<b>6</b>	<b>6/29/88</b>
	<b>5,019,400</b>	<b>5/28/91</b>	<b>Gombotz et al.</b>	<b>424</b>	<b>497</b>	<b>5/1/89</b>
	<b>5,057,318</b>	<b>10/15/91</b>	<b>Magruder et al.</b>	<b>424</b>	<b>438</b>	<b>4/23/90</b>
	<b>5,059,423</b>	<b>10/22/91</b>	<b>Magruder et al.</b>	<b>424</b>	<b>438</b>	<b>4/23/90</b>
	<b>5,061,492</b>	<b>10/29/91</b>	<b>Okada et al.</b>	<b>424</b>	<b>423</b>	<b>1/24/90</b>
	<b>5,077,033</b>	<b>12/31/91</b>	<b>Viegas et al.</b>	<b>514</b>	<b>668</b>	<b>8/7/90</b>
	<b>5,085,866</b>	<b>2/4/92</b>	<b>Cowsar et al.</b>	<b>424</b>	<b>481</b>	<b>12/2/88</b>
	<b>5,112,614</b>	<b>5/12/92</b>	<b>Magruder et al.</b>	<b>424</b>	<b>422</b>	<b>9/14/89</b>
	<b>5,137,727</b>	<b>8/11/92</b>	<b>Eckenhoff et al.</b>	<b>424</b>	<b>422</b>	<b>6/12/91</b>
	<b>5,151,093</b>	<b>9/29/92</b>	<b>Theeuwes et al.</b>	<b>604</b>	<b>892.1</b>	<b>10/29/90</b>
	<b>5,181,914</b>	<b>1/26/93</b>	<b>Zook</b>	<b>604</b>	<b>307</b>	<b>5/6/92</b>
	<b>5,209,746</b>	<b>5/11/93</b>	<b>Balaban et al.</b>	<b>604</b>	<b>892.1</b>	<b>2/18/92</b>
	<b>5,234,692</b>	<b>8/10/93</b>	<b>Magruder et al.</b>	<b>424</b>	<b>473</b>	<b>9/2/92</b>
EXAMINER:			DATE CONSIDERED:			

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> Sheet 1 of 2 PTO-1449 			ATTORNEY'S DOCKET NO.: <b>ARC 3312 R1</b>		APPLICATION NO.: <b>10/606,969</b>		
			APPLICANT: <b>Chen et al.</b>				
			FILING DATE: <b>06/25/03</b>		GROUP: <b>1615</b>		
			<b>US PATENT DOCUMENTS</b>				
	<b>5,234,693</b>	<b>8/10/93</b>	<b>Magruder et al.</b>	<b>424</b>	<b>473</b>	<b>9/2/92</b>	
	<b>5,242,910</b>	<b>9/7/93</b>	<b>Damanj</b>	<b>514</b>	<b>152</b>	<b>10/13/92</b>	
	<b>5,252,318</b>	<b>10/12/93</b>	<b>Joshi et al.</b>	<b>424</b>	<b>78.04</b>	<b>6/15/90</b>	
	<b>5,278,201</b>	<b>1/11/94</b>	<b>Dunn et al.</b>	<b>523</b>	<b>133</b>	<b>4/24/90</b>	
	<b>5,279,608</b>	<b>1/18/94</b>	<b>Cheikh</b>	<b>604</b>	<b>892.1</b>	<b>12/4/91</b>	
	<b>5,308,348</b>	<b>5/3/94</b>	<b>Balaban et al.</b>	<b>644</b>	<b>891.1</b>	<b>5/5/93</b>	
	<b>5,310,865</b>	<b>5/10/94</b>	<b>Katashi Enomoto et al.</b>	<b>528</b>	<b>361</b>	<b>12/18/92</b>	
	<b>5,324,519</b>	<b>6/28/94</b>	<b>Dunn et al.</b>	<b>424</b>	<b>426</b>	<b>10/28/91</b>	
	<b>5,300,295</b>	<b>8/5/94</b>	<b>Viegas et al.</b>	<b>424</b>	<b>427</b>	<b>9/13/91</b>	
	<b>5,336,057</b>	<b>8/9/94</b>	<b>Toshio Fukuda et al.</b>	<b>417</b>	<b>395</b>	<b>7/20/93</b>	
	<b>5,330,452</b>	<b>7/19/94</b>	<b>Zook</b>	<b>604</b>	<b>307</b>	<b>6/1/93</b>	
	<b>5,340,614</b>	<b>8/23/94</b>	<b>Perman et al.</b>	<b>427</b>	<b>2.24</b>	<b>2/11/93</b>	
	<b>5,342,627</b>	<b>8/30/627</b>	<b>Chopra et al.</b>	<b>424</b>	<b>473</b>	<b>11/12/92</b>	
	<b>5,415,866</b>	<b>5/16/95</b>	<b>Zook</b>	<b>424</b>	<b>448</b>	<b>7/12/93</b>	
	<b>5,540,912</b>	<b>7/30/96</b>	<b>Roorda et al.</b>	<b>424</b>	<b>422</b>	<b>3/30/93</b>	
	<b>5,441,732</b>	<b>8/15/95</b>	<b>Hoeg et al.</b>	<b>424</b>	<b>78.04</b>	<b>3/18/92</b>	
	<b>5,447,725</b>	<b>9/5/95</b>	<b>Damani et al.</b>	<b>424</b>	<b>435</b>	<b>6/11/93</b>	
	<b>5,456,679</b>	<b>10/10/95</b>	<b>Balaban et al.</b>	<b>604</b>	<b>892.1</b>	<b>12/7/94</b>	
	<b>5,487,897</b>	<b>1/30/96</b>	<b>Polson et al.</b>	<b>424</b>	<b>426</b>	<b>9/28/93</b>	
	<b>5,540,912</b>	<b>7/30/96</b>	<b>Roorda et al.</b>	<b>424</b>	<b>422</b>	<b>7/30/96</b>	
	<b>5,543,156</b>	<b>8/6/96</b>	<b>Roorda et al.</b>	<b>424</b>	<b>484</b>	<b>1/21/94</b>	
	<b>5,556,905</b>	<b>9/17/96</b>	<b>Frappier et al.</b>	<b>524</b>	<b>311</b>	<b>3/30/94</b>	
	<b>5,571,525</b>	<b>11/5/96</b>	<b>Roorda et al.</b>	<b>424</b>	<b>426</b>	<b>3/30/94</b>	
	<b>5,787,175</b>	<b>12/24/96</b>	<b>Viegas et al.</b>	<b>424</b>	<b>427</b>	<b>12/28/93</b>	
	<b>5,599,534</b>	<b>2/4/97</b>	<b>Himmelstein et al.</b>	<b>424</b>	<b>78.04</b>	<b>8/9/94</b>	
	<b>5,599,552</b>	<b>2/4/97</b>	<b>Dunn et al.</b>	<b>424</b>	<b>423</b>	<b>5/26/94</b>	
	<b>5,610,184</b>	<b>3/11/97</b>	<b>Shahinian, Jr.</b>	<b>514</b>	<b>540</b>	<b>3/3/95</b>	
	<b>5,618,563</b>	<b>4/8/97</b>	<b>Berde et al.</b>	<b>424</b>	<b>501</b>	<b>9/10/93</b>	
	<b>5,620,700</b>	<b>4/15/97</b>	<b>Berggen et al.</b>	<b>424</b>	<b>435</b>	<b>5/9/95</b>	
	<b>5,651,986</b>	<b>7/29/97</b>	<b>Brem et al.</b>	<b>424</b>	<b>484</b>	<b>6/14/96</b>	
	<b>5,654,010</b>	<b>8/5/97</b>	<b>Johnson et al.</b>	<b>424</b>	<b>502</b>	<b>7/7/95</b>	
EXAMINER:				DATE CONSIDERED:			

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION Sheet 1 of 3 PTO-1449			ATTORNEY'S DOCKET NO.: ARC 3312 R1	APPLICATION NO.: 10/606,969		
			APPLICANT: Chen et al.			
			FILING DATE: 06/25/03	GROUP: 1615		
<b>US PATENT DOCUMENTS</b>						
	5,656,297	8/12/97	Bernstein et al.	424	484	5/3/94
	5,660,817	8/26/97	Masterman et al.	424	49	11/9/94
	5,674,292	10/7/97	Tucker et al.	623	16	7/7/95
	5,618,563	4/8/97	Berde et al.	424	501	9/10/93
	5,681,873	10/28/97	Norton et al.	523	115	10/14/93
	5,700,485	12/23/97	Berde et al.	424	501	5/1/95
	5,707,664	1/13/98	Illum	424	434	12/20/94
	5,708,011	1/13/98	Bardsley et al.	514	330	10/13/94
	5,733,950	3/31/98	Dunn et al.	523	113	9/25/95
	5,744,153	4/28/98	Yewey et al.	424	426	6/9/97
	5,747,058	5/5/98	Tipton et al.	424	337	6/7/95
	5,747,060	5/5/98	Sackler et al.	424	426	3/26/96
	5,759,563	6/2/98	Yewey et al.	424	426	6/7/95
	5,760,077	6/2/98	Shahinian Jr.	514	540	3/11/97
	5,766,637	6/16/98	Shine et al.	424	497	10/8/96
	5,780,044	7/14/98	Yewey et al.	424	426	12/5/96
	5,783,205	7/21/98	Berggren et al.	424	426	4/10/97
	5,804,212	9/8/98	Illum	424	434	6/17/97
	5,849,763	12/15/98	Bardsley et al.	514	445	10/27/95
	5,910,502	6/8/99	Gennery	514	330	3/3/98
	5,922,340	7/13/99	Berde et al.	424	426	9/16/96
	5,942,241	8/24/99	Chasin et al.	424	426	6/7/96
	5,955,479	9/21/99	Bardsley et al.	514	330	10/13/94
	5,958,443	9/28/99	Viegas et al.	424	427	12/23/96
	5,972,326	10/26/99	Galin et al.	424	78.04	3/18/97
	5,972,366	10/26/99	Haynes et al.	424	422	9/17/96
	5,990,194	11/23/99	Dunn et al.	523	113	11/7/97
	5,919,835	7/6/99	Domb et al.	523	113	12/23/92
	6,004,295	12/21/99	Langer et al.	604	164	6/26/98
	6,046,187	4/4/00	Berde et al.	514	180	9/16/96
	6,050,986	4/18/00	Hektner	604	508	12/1/97
EXAMINER:			DATE CONSIDERED:			

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE CITATION</b> Sheet 1 of 4 PTO-1449			ATTORNEY'S DOCKET NO.: <b>ARC 3312 R1</b>		APPLICATION NO.: <b>10/606,969</b>	
			APPLICANT: <b>Chen et al.</b>			
			FILING DATE: <b>06/25/03</b>	GROUP: <b>1615</b>		
<b>US PATENT DOCUMENTS</b>						
	<b>6,086,909</b>	<b>7/11/00</b>	<b>Harrison et al.</b>	<b>424</b>	<b>430</b>	<b>2/12/99</b>
	<b>6,103,266</b>	<b>8/15/00</b>	<b>Tapolski et al.</b>	<b>424</b>	<b>484</b>	<b>4/22/98</b>
	<b>6,106,301</b>	<b>8/22/00</b>	<b>Merril</b>	<b>434</b>	<b>262</b>	<b>9/4/97</b>
	<b>6,117,425</b>	<b>9/12/00</b>	<b>McPhee et al.</b>	<b>424</b>	<b>94.64</b>	<b>7/7/95</b>
	<b>6,120,789</b>	<b>9/19/00</b>	<b>Dunn</b>	<b>424</b>	<b>426</b>	<b>3/30/99</b>
	<b>6,120,804</b>	<b>9/19/00</b>	<b>Drizen et al.</b>	<b>424</b>	<b>488</b>	<b>4/8/99</b>
	<b>6,129,933</b>	<b>10/10/00</b>	<b>Oshlack et al.</b>	<b>424</b>	<b>495</b>	<b>7/24/97</b>
	<b>6,130,200</b>	<b>10/10/00</b>	<b>Brodbeck et al.</b>	<b>514</b>	<b>2</b>	<b>12/18/97</b>
	<b>6,136,334</b>	<b>10/24/00</b>	<b>Viegas et al.</b>	<b>424</b>	<b>427</b>	<b>6/11/97</b>
	<b>6,143,314</b>	<b>11/7/00</b>	<b>Chandeashekhar et al.</b>	<b>424</b>	<b>426</b>	<b>10/28/98</b>
	<b>6,193,991</b>	<b>2/27/01</b>	<b>Shukla</b>	<b>424</b>	<b>426</b>	<b>10/28/98</b>
	<b>6,193,994</b>	<b>2/27/01</b>	<b>Lee et al.</b>	<b>424</b>	<b>444</b>	<b>5/22/97</b>
	<b>6,197,327</b>	<b>3/6/01</b>	<b>Harrison et al.</b>	<b>424</b>	<b>430</b>	<b>5/15/98</b>
	<b>6,214,387</b>	<b>4/10/01</b>	<b>Berde et al.</b>	<b>424</b>	<b>501</b>	<b>9/17/97</b>
	<b>6,217,911</b>	<b>4/17/01</b>	<b>Vaung et al.</b>	<b>424</b>	<b>501</b>	<b>7/5/96</b>
	<b>6,238,702</b>	<b>5/29/01</b>	<b>Berde et al.</b>	<b>424</b>	<b>489</b>	<b>7/12/99</b>
	<b>6,248,345</b>	<b>6/19/01</b>	<b>Goldenheim et al.</b>	<b>424</b>	<b>426</b>	<b>7/2/98</b>
	<b>6,255,502</b>	<b>7/3/01</b>	<b>Penkler et al.</b>	<b>552</b>	<b>549</b>	<b>7/11/97</b>
	<b>6,261,547</b>	<b>7/17/01</b>	<b>Bawa et al.</b>	<b>424</b>	<b>78.04</b>	<b>11/23/99</b>
	<b>6,309,375</b>	<b>10/30/01</b>	<b>Glines et al.</b>	<b>604</b>	<b>187</b>	<b>5/18/99</b>
	<b>6,322,548</b>	<b>11/27/01</b>	<b>Payne et al.</b>	<b>604</b>	<b>500</b>	<b>3/31/98</b>
	<b>6,352,667</b>	<b>3/5/02</b>	<b>English</b>	<b>264</b>	<b>328.17</b>	<b>8/24/99</b>
	<b>6,355,273</b>	<b>3/12/02</b>	<b>Carli et al.</b>	<b>424</b>	<b>489</b>	<b>8/4/00</b>
	<b>6,372,245</b>	<b>4/16/02</b>	<b>Bowman et al.</b>	<b>424</b>	<b>427</b>	<b>4/22/94</b>
	<b>6,375,659</b>	<b>4/24/02</b>	<b>Erbe et al.</b>	<b>606</b>	<b>94</b>	<b>2/20/01</b>
	<b>6,395,293</b>	<b>5/28/02</b>	<b>Polson et al.</b>	<b>424</b>	<b>426</b>	<b>3/8/00</b>
	<b>6,403,057</b>	<b>6/11/02</b>	<b>Schneider et al.</b>	<b>424</b>	<b>9.52</b>	<b>6/23/00</b>
	<b>6,417,201</b>	<b>7/9/02</b>	<b>Bardsley et al.</b>	<b>514</b>	<b>330</b>	<b>7/12/00</b>
	<b>6,426,339</b>	<b>7/30/02</b>	<b>Berde et al.</b>	<b>514</b>	<b>180</b>	<b>4/3/00</b>
	<b>6,432,415</b>	<b>8/13/02</b>	<b>Osborne et al.</b>	<b>424</b>	<b>400</b>	<b>12/17/99</b>
	<b>6,423,818</b>	<b>7/23/02</b>	<b>Matsuda et al.</b>	<b>528</b>	<b>354</b>	<b>7/26/00</b>
	<b>6,451,346</b>	<b>9/17/02</b>	<b>Shah</b>	<b>424</b>	<b>486</b>	<b>12/23/98</b>
	<b>6,543,081</b>	<b>3/18/03</b>	<b>Goldenheim et al.</b>	<b>424</b>	<b>426</b>	<b>4/2/01</b>
EXAMINER:				DATE CONSIDERED:		

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE CITATION</b> Sheet 1 of 5 PTO-1449			ATTORNEY'S DOCKET NO.: <b>ARC 3312 R1</b>		APPLICATION NO.: <b>10/606,969</b>	
			APPLICANT: <b>Chen et al.</b>			
			FILING DATE: <b>06/25/03</b>		GROUP: <b>1615</b>	
<b>US PATENT DOCUMENTS</b>						
	<b>US 2001/0004644 A1</b>	<b>6/21/01</b>	<b>Levin</b>	<b>514</b>	<b>646</b>	<b>12/15/00</b>
	<b>US 2001/0046518 A1</b>	<b>11/29/01</b>	<b>Sawhney</b>	<b>424</b>	<b>486</b>	<b>8/14/98</b>
	<b>US 2001/0055607 A1</b>	<b>12/27/01</b>	<b>Levin</b>	<b>424</b>	<b>435</b>	<b>7/17/98</b>
	<b>US 2002/0015712 A1</b>	<b>2/7/02</b>	<b>McHride et al.</b>	<b>424</b>	<b>400</b>	<b>5/23/00</b>
	<b>US 2002/0001608 A1</b>	<b>1/3/02</b>	<b>Polson et al.</b>	<b>424</b>	<b>426</b>	<b>3/8/00</b>
	<b>US 2002/0010150 A1</b>	<b>1/24/02</b>	<b>Cortese et al.</b>	<b>514</b>	<b>54</b>	<b>4/26/01</b>
	<b>US 2002/0016338 A1</b>	<b>2/7/02</b>	<b>Mather et al.</b>	<b>514</b>	<b>317</b>	<b>10/1/01</b>
	<b>US 2002/0028243 A1</b>	<b>3/7/02</b>	<b>Masters</b>	<b>424</b>	<b>484</b>	<b>2/28/01</b>
	<b>US 2002/0028181 A1</b>	<b>3/7/02</b>	<b>Miller et al.</b>	<b>424</b>	<b>43</b>	<b>4/26/01</b>
	<b>US 2002/0037104 A1</b>	<b>11/1/01</b>	<b>Zhang et al.</b>	<b>604</b>	<b>502</b>	<b>2/28/01</b>
	<b>US 2002/0037358 A1</b>	<b>3/28/02</b>	<b>Barry et al.</b>	<b>427</b>	<b>2.1</b>	<b>10/18/01</b>
	<b>US 2002/0039594 A1</b>	<b>4/4/02</b>	<b>Unger</b>	<b>424</b>	<b>426</b>	<b>5/11/98</b>
	<b>US 2002/0004063 A1</b>	<b>1/10/02</b>	<b>Zhang</b>	<b>424</b>	<b>443</b>	<b>9/28/99</b>
	<b>US 2002/0045668 A1</b>	<b>4/18/02</b>	<b>Dang et al.</b>	<b>514</b>	<b>649</b>	<b>7/17/01</b>
	<b>US 2002/0054915 A1</b>	<b>5/9/02</b>	<b>Goldenheim et al.</b>	<b>424</b>	<b>497</b>	<b>4/2/01</b>
	<b>US 2002/0061326 A1</b>	<b>5/23/02</b>	<b>Wei-Ping Li et al.</b>	<b>424</b>	<b>424</b>	<b>1/2/01</b>
	<b>US 2002/0086971 A1</b>	<b>7/14/02</b>	<b>Pham</b>	<b>528</b>	<b>354</b>	<b>2/1/02</b>
<b>FOREIGN PATENT DOCUMENTS</b>						
	<b>WO 93/24150</b>	<b>PCT</b>				
	<b>WO 95/13799</b>	<b>PCT</b>				
	<b>WO 98/27962</b>	<b>PCT</b>				
	<b>WO 98/27963</b>	<b>PCT</b>				
	<b>WO 99/47073</b>	<b>PCT</b>				
	<b>WO 00/74650 A2</b>	<b>PCT</b>				
	<b>WO 02/058670 A1</b>	<b>PCT</b>				
	<b>WO 02/067991 A1</b>	<b>PCT</b>				
	<b>WO 03/041685 A1</b>	<b>PCT</b>				
	<b>WO 03/041684 A2</b>	<b>PCT</b>				
	<b>WO 03/041757 A2</b>	<b>PCT</b>				
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages etc.)</b>						
	<b>Cleland, J. L. "Injectable Gels for Local and Systemic Delivery of Proteins," <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i>, Vol. 28, 2001.</b>					
EXAMINER:			DATE CONSIDERED:			

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION Sheet 1 of 6 PTO-1449		ATTORNEY'S DOCKET NO.: ARC 3312 R1	APPLICATION NO.: 10/606,969
		APPLICANT: Chen et al.	
		FILING DATE: 06/25/03	GROUP: 1615
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages etc.)			
Blanco, M. D. et al. "Bupivacaine-loaded comatrix formed by alumin microspheres included in a poly(lactide-coglycolide) film: in vivo biocompatibility and drug release studies," <u>Biomaterials</u> , Vol. 20, pp.1919-1924, 1999.			
Duenas, E. et al. "Sustained Delivery of rhVEGF from a Novel Injectable Liquid, Plad" <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> , Vol. 28, 2001.			
Guevello, P. Le et al. "High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics," <u>Journal of Chromatography</u> , Vol. 622, pp. 284-290, (1993).			
Garry, M. G. et al. "Evaluation of the efficiency of a bioerodible bupivacaine polymer system on antinociception and inflammatory mediator release," <u>Pain</u> , vol. 82, pp. 49-55, 1999.			
Lambert, W. J. et al. "Development of an in situ forming biodegradable poly-lactide-co-glycolid system for controlled release of proteins," <u>Journal of Controlled Release</u> , Vol. 33, pp. 189-195 (1995).			
Okumu, F. W. et al. "Sustained Delivery of Growth Hormone from a Novel Injectable Liquid, Plad," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> , Vol. 28, 2001.			
Okumu, F. W. et al. "Evaluation of the Saber™ Delivery System for Sustained Release of Growth Hormone – Formulation Design and <i>In Vivo</i> Assessment," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> , Vol. 28, 2001.			
Philip, B. K. et al. "The Economic Impact of Opioids on Postoperative Pain Management," <u>Journal of Clinical Anesthesia</u> , Vol. 14, pp. 354-364, 2002.			
EXAMINER:		DATE CONSIDERED:	

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.